Is Ajooni Biotech overvalued or undervalued?

As of 27 May 2025, Ajooni Biotech's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived worth. The company appears to be undervalued based on its current metrics. Key ratios include a PE ratio of 28.81, an EV to EBITDA of 22.14, and a Price to Book Value of 1.11, which suggest that the stock is trading at a reasonable price relative to its earnings and assets.
In comparison to its peers, Ajooni Biotech's PE ratio is similar to that of its closest competitor, while the industry average for EV to EBITDA is typically lower, indicating potential for growth. Notably, Ajooni Biotech's PEG ratio is at 0.00, which may suggest that the stock is undervalued relative to its growth prospects. Despite recent underperformance against the Sensex, particularly over the past year and three years, the long-term return of 395.19% over five years highlights its potential for recovery and growth.